Drug Profile
Japanese encephalitis vaccine - Rhein Biotech
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Rhein Biotech
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Encephalitis virus infections
Most Recent Events
- 13 Oct 2004 Discontinued - Preclinical for Encephalitis virus infections in Netherlands (unspecified route)
- 31 Dec 2003 Crucell's PER.C6 technology is no longer licensed to Rhein Biotech
- 31 Oct 2002 Rhein Biotech has been acquired by Berna Biotech